News

ASH 2020: Early Trial for Bispecific Antibody in Non-Hodgkin Lymphoma Shows High Response Rate

Odronextamab, a bispecific antibody targeting CD20 and CD3, led to response rates as high as 90 percent in patients with refractory B-cell non-Hodgkin lymphoma (B-NHL), including patients who underwent chimeric antigen receptor (CAR) T cell therapy, according to early trials results.

ASH 2020: Chemotherapy-Free Combination Treatment for Chronic Lymphocytic Leukemia Reveals High One-Year Disease-Free Survival Rate

A time-limited, frontline combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) shows to mobilize and clear CLL leading to deep responses for patients who achieved undetectable minimal residual disease (MRD) status, according to results from the CAPTIVATE study.

ASH 2020: ZUMA-12 Trial Exhibits Promising Results in Frontline CAR T Treatment for Aggressive Lymphoma

Axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T cell therapy, appeared an effective frontline (initial) treatment for high-risk large B-cell lymphomas.

Addressing Cancer Survivorship

Emily Tonorezos, MD, MPH, Director of the Office of Cancer Survivorship at the National Cancer Institute (NCI), in the Division of Cancer Control & Population Sciences, shares what she and the agency are doing to raise awareness of and address issues that cancer survivors may face, as well as future directions in cancer survivorship research.

Patient Perspectives: Understanding Telemedicine

With telemedicine trending to be a mainstay in how healthcare professionals treat patients, Ameet Doshi, MD, MBA, Lead Hospitalist for Telemedicine at HealthPartners, shares what is contributing to the surge and how it affects lymphoma patients and survivors.

U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (liso-cel, BREYANZI) for Large B-cell Lymphoma

Lisocabtagene maraleucel (BREYANZI) is the fourth chimeric antigen receptor (CAR) T cell therapy approved for certain types of non-Hodgkin lymphoma (NHL).

U.S. Food and Drug Administration Approves Umbralisib (UKONIQ) for Marginal Zone Lymphoma and Follicular Lymphoma

Umbralisib (UKONIQ, TG Therapeutics), a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, has been approved for relapsed or refractory marginal zone lymphoma and follicular lymphoma.

LRF Publishes Proceedings of the Inaugural International Marginal Zone Lymphoma Scientific Workshop

The white paper provides a summary of the workshop proceedings, presents the key findings of each speaker, and highlights the unmet needs identified during the post-workshop discussion with suggested immediate and long-term solutions.

LRF Urges CDC to Prioritize Blood Cancer Patients for COVID-19 Vaccine

LRF Urges CDC to Prioritize Blood Cancer Patients for COVID-19 Vaccine VISIT THE COVID-19 LEARNING CENTER FOR MORE UPDATES AND HELPFUL RESOURCES The well-being of the lymphoma community is the top priority of the Lymphoma Research Foundation (LRF). People with cancer, who…

Ask the Doctor: Should CLL patients receive the COVID vaccine while they are on treatment with BTK inhibitors considering that they have to stay on them indefinitely?

Ask the Doctor: Should CLL patients receive the COVID vaccine while they are on treatment with BTK inhibitors considering that they have to stay on them indefinitely? As of January 2021, there are two COVID-19 vaccines that have been approved…

Subscribe to Our Emails. Get lymphoma and CLL resources and updates.